Table 1. Tumour samples utilized to profile MSI.
| Tumour type | Abbreviation | Samples | MSI-Hs (frequency) |
|---|---|---|---|
| Uterine corpus endometrial carcinoma | UCEC | 265 | 75 (28.3%) |
| Stomach adenocarcinoma | STAD | 292 | 64 (21.9%) |
| Colon adenocarcinoma | COAD | 271 | 45 (16.6%) |
| Rectal adenocarcinoma | READ | 76 | 3; 4* (9.2%) |
| Adrenal cortical carcinoma | ACC | 92 | 5* (5.4%) |
| Oesophageal carcinoma | ESCA | 183 | 3; 3* (3.3%) |
| Ovarian cancer | OV | 436 | 14* (3.2%) |
| Liver hepatocellular carcinoma | LIHC | 375 | 11* (2.9%) |
| Cervical squamous cell carcinoma | CESC | 305 | 7* (2.3%) |
| Breast cancer | BRCA | 922 | 16* (1.7%) |
| Glioblastoma multiforme | GBM | 316 | 4* (1,3%) |
| Head and neck squamous cell carcinoma | HNSC | 505 | 6* (1.2%) |
| Lung squamous cell carcinoma | LUSC | 407 | 5* (1.2%) |
| Kidney renal clear cell carcinoma | KIRC | 377 | 4* (1.1%) |
| Pancreatic cancer | PAC | 171 | 2* (1.1%) |
| Urothelial bladder cancer | BLCA | 368 | 2* (0.8%) |
| Papillary kidney carcinoma | KIRP | 286 | 2* (0.7%) |
| Low grade glioma | LGG | 514 | 3* (0.6%) |
| Prostate adenocarcinoma | PRAD | 497 | 3* (0.6%) |
| Lung adenocarcinoma | LUAD | 482 | 1* (0.2%) |
| Cutaneous melanoma | SKCM | 109 | 0* (0%) |
| Pheochromocytoma and paraganglioma | PHCA | 176 | 0* (0%) |
| Thyroid cancer | THCA | 493 | 0* (0%) |
| Total | 7,919 | 281 |
The Abbreviation column indicates the cancer type abbreviations used throughout the manuscript. The number of cases predicted as MSI-H at a confidence level of 0.75 is indicated with `*' (see subsection `Prediction of MSI status from exome-sequencing data').